August 21, 2024
FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues
Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment
Biogen Faces Lawsuit Over Alleged Kickback Scheme to Block Generic Competition for Multiple Sclerosis Drug Tecfidera
Biogen, kickback scheme, Tecfidera, generics, multiple sclerosis, PBM, lawsuit
Alaskans Can Virtually Manage Diabetes Risk for Free with Omada Health
Omada Health, Diabetes Management, Virtual Chronic Care, Alaska, Free Program
US Lawmakers Demand FDA Probe into Clinical Trials Linked to China’s Military
FDA investigation, clinical trials, China’s military, US lawmakers, bipartisan scrutiny
Bayer Pharma’s Overhaul Not Slowing Down Deal Making, Says BD Chief
Bayer Pharma, deal making, group overhaul, biotech, pharmaceutical industry
Bavarian Nordic Ramps Up Mpox Vaccine Production to Combat Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Jynneos, Global Health Emergency, Africa CDC, WHO
FTC Supports FDA’s Simplified Biosimilar Interchangeability Plan
biosimilars, interchangeable biosimilars, FDA, FTC, pharmaceutical competition, drug pricing
Merck & Co. Expands Oncology Pipeline with Kelun-Biotech ADCs
Merck & Co., Kelun-Biotech, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Oncology Pipeline
Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults
tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound